Nothing Special   »   [go: up one dir, main page]

DOP2015000001A - Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-4 morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida - Google Patents

Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-4 morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Info

Publication number
DOP2015000001A
DOP2015000001A DO2015000001A DO2015000001A DOP2015000001A DO P2015000001 A DOP2015000001 A DO P2015000001A DO 2015000001 A DO2015000001 A DO 2015000001A DO 2015000001 A DO2015000001 A DO 2015000001A DO P2015000001 A DOP2015000001 A DO P2015000001A
Authority
DO
Dominican Republic
Prior art keywords
oxo
oxazolidin
phenyl
methyl
pharmaceutical administration
Prior art date
Application number
DO2015000001A
Other languages
English (en)
Inventor
Heike Neumann
Wolfgang Mück
Klaus Benke
Original Assignee
Bayer Pharma Aktiensellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiensellschaft filed Critical Bayer Pharma Aktiensellschaft
Publication of DOP2015000001A publication Critical patent/DOP2015000001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a formas de administración farmacéuticas administrables por vía oral sólidas que comprenden 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida (rivaroxabán, compuesto activo (I)), caracterizadas porque se libera rápidamente una cantidad parcial del compuesto activo (I) y se libera una cantidad parcial de una forma controlada (modificada, retardada, pospuesta), y a procedimientos para su preparación, a su uso como medicamentos y a su uso para la profilaxis, profilaxis secundaria o tratamiento de trastornos.
DO2015000001A 2012-07-03 2015-01-02 Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-4 morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida DOP2015000001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03

Publications (1)

Publication Number Publication Date
DOP2015000001A true DOP2015000001A (es) 2015-07-15

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000001A DOP2015000001A (es) 2012-07-03 2015-01-02 Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-4 morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Country Status (33)

Country Link
US (2) US20140010876A1 (es)
EP (1) EP2869814B1 (es)
JP (1) JP6166781B2 (es)
KR (1) KR20150027284A (es)
CN (1) CN104582684A (es)
AP (1) AP3756A (es)
AR (1) AR091621A1 (es)
AU (1) AU2013286068A1 (es)
BR (1) BR112015000043A2 (es)
CA (1) CA2878123A1 (es)
CL (1) CL2015000002A1 (es)
CO (1) CO7240379A2 (es)
CR (1) CR20150001A (es)
CU (1) CU20140152A7 (es)
DO (1) DOP2015000001A (es)
EA (1) EA025016B1 (es)
EC (1) ECSP14033581A (es)
ES (1) ES2574627T3 (es)
GT (1) GT201400306A (es)
HK (1) HK1209635A1 (es)
IL (1) IL236455A0 (es)
IN (1) IN2014DN11066A (es)
MA (1) MA37721B1 (es)
MX (1) MX2015000053A (es)
NZ (1) NZ703733A (es)
PE (1) PE20150189A1 (es)
PH (1) PH12014502833A1 (es)
SG (1) SG11201408420YA (es)
TN (1) TN2014000541A1 (es)
TW (1) TW201414508A (es)
UY (1) UY34856A (es)
WO (1) WO2014005934A1 (es)
ZA (1) ZA201500759B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
EP3978072A1 (en) * 2016-02-23 2022-04-06 Morgandane Scientific, LLC Method of treating patients coadministered a factor xa inhibitor and verapamil
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
US20210283046A1 (en) * 2018-07-24 2021-09-16 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
JOP20210019A1 (ar) * 2018-07-24 2021-01-24 Bayer Ag شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
EP1083879B1 (en) * 1998-06-03 2004-09-29 Alza Corporation Devices for providing prolonged drug therapy
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
RU2351316C2 (ru) * 2003-09-02 2009-04-10 Пфайзер Продактс Инк. Лекарственные формы с замедленным высвобождением зипразидона
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
CA2729979A1 (en) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
MX2012015188A (es) * 2010-06-22 2013-05-20 Twi Pharmaceuticals Inc Composiciones de liberacion controlada con efecto de alimentos reducido.

Also Published As

Publication number Publication date
AU2013286068A1 (en) 2015-01-29
IL236455A0 (en) 2015-02-26
JP2015521648A (ja) 2015-07-30
IN2014DN11066A (es) 2015-09-25
ECSP14033581A (es) 2015-12-31
CR20150001A (es) 2015-02-06
CN104582684A (zh) 2015-04-29
EP2869814A1 (de) 2015-05-13
CA2878123A1 (en) 2014-01-09
TW201414508A (zh) 2014-04-16
UY34856A (es) 2013-12-31
EP2869814B1 (de) 2016-04-06
MA37721B1 (fr) 2016-12-30
CO7240379A2 (es) 2015-04-17
EA025016B1 (ru) 2016-11-30
GT201400306A (es) 2015-08-25
WO2014005934A1 (de) 2014-01-09
SG11201408420YA (en) 2015-01-29
PH12014502833A1 (en) 2015-02-02
MX2015000053A (es) 2015-04-10
TN2014000541A1 (en) 2016-03-30
CL2015000002A1 (es) 2015-05-29
ZA201500759B (en) 2017-11-29
AP2015008208A0 (en) 2015-01-31
US20140010876A1 (en) 2014-01-09
BR112015000043A2 (pt) 2017-06-27
EA201590142A1 (ru) 2015-06-30
NZ703733A (en) 2016-12-23
AP3756A (en) 2016-07-31
MA37721A1 (fr) 2016-05-31
JP6166781B2 (ja) 2017-07-19
PE20150189A1 (es) 2015-01-31
CU20140152A7 (es) 2015-10-27
ES2574627T3 (es) 2016-06-21
KR20150027284A (ko) 2015-03-11
US20150125527A1 (en) 2015-05-07
HK1209635A1 (en) 2016-04-08
AR091621A1 (es) 2015-02-18

Similar Documents

Publication Publication Date Title
DOP2015000001A (es) Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-4 morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
ECSP088339A (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
BRPI0519376A2 (pt) formas de administraÇço farmacÊuticas sàlidas, aplicÁveis por via oral, contendo rivaroxaban com liberaÇço modificada
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
PH12015501625A1 (en) Aldehyde derivative of substitute oxazolidinones
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
CU20070150A7 (es) Formas de dosificacion farmacéutica sólidas administrables por vía oral con liberación modificada
UY29305A1 (es) Formas de dosificación farmacéutica sólidas administrables por vía oral con liberación modificada
NO20081982L (no) Faste, oralt administrerbare farmasoytiske doseringsformer med rask frigivelse av aktiv forbindelse
DOP2004001034A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada